AI-Driven Automation In eCTD Submissions: Opportunities And Implementation For Indian Pharmaceutical Industry

The pharmaceutical industry is one of the most regulated sectors globally, requiring extensive documentation to ensure the safety, quality, and effectiveness of medicines. Regulatory submissions are crucial for obtaining marketing authorization, clinical trial approval, and maintaining compliance throughout a product's lifecycle. ¹To standardize submissions across different regions, the International Council for Harmonization (ICH) developed the Common Technical Document (CTD), which was later updated to the Electronic Common Technical Document (eCTD) for digital submissions.²

CTD and eCTD dossiers contain detailed information on product quality, manufacturing, non-clinical studies, clinical data, safety, and effectiveness. Traditionally, preparing a dossier involves a lot of manual work, including compiling documents, formatting, validating, cross-referencing, and managing the lifecycle. Growing regulatory demands have made submission management more complicated, resulting in higher workloads, longer timelines, and an increased risk of documentation errors.²

Recent advances in digital technologies have changed how pharmaceutical regulatory operations work. Artificial Intelligence (AI), Machine Learning (ML), Natural Language Processing (NLP), and Robotic Process Automation (RPA) are increasingly used to automate tasks like document classification, metadata generation, validation, compliance monitoring, and regulatory intelligence. These technologies improve efficiency, lessen manual work, and enhance the quality of submissions.³

The launch of eCTD 4.0 has opened up more opportunities for automation within a structured, metadata-driven, and user-friendly submission framework. Its stronger lifecycle management and data handling capabilities make it a good fit for AI-enabled regulatory systems. This review focuses on how AI-driven automation can assist with eCTD submissions, highlighting applications, benefits, challenges, and future prospects, especially in the Indian pharmaceutical industry.^1,3

1.1 Evolution of CTD and eCTD Systems

The creation of the Common Technical Document (CTD) and its electronic version, eCTD, has greatly improved pharmaceutical regulatory submissions. It has increased global standardization, submission efficiency, and communication between pharmaceutical companies and regulatory bodies. Advances in digital technologies have further sped up the adoption of modern electronic submission standards.³

2. COMMON TECHNICAL DOCUMENT (CTD)

The Common Technical Document (CTD) was developed by ICH to establish a standardized format for regulatory submissions across various regions.⁴

2.1 Objectives of CTD

• Standardize regulatory dossier structure 
• Reduce duplication of documentation 
• Support simultaneous global submissions 
• Improve consistency in regulatory review 
• Enhance communication between applicants and regulatory authorities 

Before the CTD was implemented, companies created different dossier formats for various regulatory agencies. This approach led to increased workloads, higher costs, and slower approvals. The CTD addressed these challenges by providing a globally accepted standardized structure.^4,5

2.2 Structure of CTD

The CTD consists of five modules:

• Module 1 – Regional Administrative Information 
• Module 2 – Summaries and Overviews 
• Module 3 – Quality (CMC) 
• Module 4 – Nonclinical Reports 
• Module 5 – Clinical Study Reports

2.3 Transition from CTD to eCTD

As pharmaceutical development grew more complex, paper-based CTD submissions posed challenges in document management, version control, and global submissions.⁹

2.3.1 Limitations of Paper-Based CTD

• Extensive manual documentation 
• Large physical storage requirements 
• Difficulty tracking document revisions 
• Increased submission errors 
• Longer review timelines 

To overcome these limitations, the pharmaceutical industry embraced the Electronic Common Technical Document (eCTD), converting traditional paper dossiers into a structured electronic format.^6,7

3. ELECTRONIC COMMON TECHNICAL DOCUMENT (eCTD):

The Electronic Common Technical Document (eCTD) is an electronic version of the CTD format that uses an XML-based standardized structure for regulatory submissions.^5,9

3.1 Major Features of eCTD⁶

• Electronic document management 
• XML-based framework 
• Hyperlinking and bookmarking 
• Automated validation checks 
• Lifecycle management and version control 
• Improved document retrieval

3.2 Benefits of eCTD

• Faster submission preparation and review 
• Reduced administrative workload 
• Improved traceability and compliance 
• Better communication with regulatory agencies 
• Reduced paper usage and storage costs ⁸

3.3 Evolution of eCTD Versions

The evolution of eCTD from a basic electronic submission format to an advanced digital framework has enhanced submission quality, lifecycle management, traceability, and regulatory efficiency. Modern eCTD systems also support AI-driven automation technologies.⁵

Figure No.05: Technical structure of eCTD 4.0

Fig. No. 03: AI driven automation across the eCTD submission lifecycle

Barrier	Description	Impact
High Cost	Expensive AI software and infrastructure	Limits adoption
Skilled Workforce Shortage	Lack of AI and eCTD experts	Reduces efficiency
Poor Digital Infrastructure	Dependence on traditional systems	Slows automation
Data Security Concerns	Sensitive regulatory data risks	Compliance issues
Limited Regulatory Guidelines	Few CDSCO AI regulations	Implementation uncertainty
Interoperability Issues	Difficulty integrating systems	Workflow inefficiency
Resistance to Change	Hesitation in adopting new technology	Delays automation
Validation Challenges	Need for continuous AI validation	Affects regulatory acceptance
Limited eCTD 4.0 Awareness	Slow transition from older systems	Delays modernization
Manual Documentation Dependence	Continued use of manual processes	Increases errors and delays

Table No.05: Barriers to AI-Driven eCTD Implementation in India

Figure No. 06: Timeline for implantation of eCTD 4.0^[11]

5.2 Future Prospects of Artificial Intelligence in Regulatory Affairs 

The function of Artificial Intelligence (AI) in pharmaceutical regulatory matters is anticipated to grow considerably with the continuous progress of digital technologies. New systems like AI-driven dossier management platforms, predictive regulatory analytics, cloud-based regulatory solutions, and smart document processing tools could modernize conventional regulatory operations and enhance overall workflow efficiency.⁴²

Prospective AI applications might enable automatic document categorization, metadata creation, compliance evaluation, lifecycle monitoring, and regulatory insights. Technologies such as Machine Learning (ML) and Natural Language Processing (NLP) can aid in examining extensive amounts of regulatory data, spotting possible compliance concerns, and facilitating quicker and more uniform decision-making procedures.⁴³

The adoption of eCTD 4.0 alongside AI technologies is expected to boost submission quality, improve traceability, shorten review timelines, and reinforce global regulatory alignment. Moreover, sophisticated digital technologies like cloud computing, blockchain systems, and organized content management solutions could enhance transparency, interoperability, and secure data sharing in regulatory frameworks.⁴⁴

With the ongoing evolution of pharmaceutical regulatory systems towards digital transformation, AI-supported regulatory operations are anticipated to assume a more significant role in contemporary submission management. Additionally, implementing explainable AI and organized digital workflows could enhance regulatory confidence, uniformity, and acceptance of AI-driven procedures in pharmaceutical regulatory affairs.⁴⁵

6.  KEY FINDINGS

• Artificial Intelligence supports improved efficiency and accuracy in eCTD submission processes.
• Technologies such as NLP and ML assist in automated document review and validation activities.
• eCTD 4.0 promotes structured, interoperable, and digitally optimized regulatory submissions.
• AI-assisted systems help reduce repetitive manual tasks and improve workflow coordination.
• India is gradually moving toward digital regulatory transformation through initiatives such as the CDSCO SUGAM platform.
• Challenges including regulatory harmonization, infrastructure readiness, validation standards, and workforce training continue to influence implementation.

6.1 Research Gap

Existing literature has widely explored the role of Artificial Intelligence (AI) in pharmaceutical regulatory operations; however, comparatively fewer studies have examined its practical application in automating electronic Common Technical Document (eCTD) submissions, particularly in the context of the Indian pharmaceutical sector. Areas such as implementation readiness, regulatory alignment, infrastructure limitations, explainable AI practices, and availability of trained professionals still require deeper investigation. In view of these gaps, the present review focuses on understanding the emerging role of AI in eCTD submissions, along with its applications, benefits, limitations, and future potential in pharmaceutical regulatory affairs.

7. AIM AND OBJECTIVES:

7.1 Aim: AI-Driven Automation in eCTD Submissions: Opportunities and Implementation for Indian Pharmaceutical Industry

7.2 Objective:

1. To study the role of Artificial Intelligence (AI) and automation technologies in eCTD submission systems.
2. To compare CTD, eCTD 3.2.2, and eCTD 4.0 with respect to automation, lifecycle management, and regulatory efficiency.
3. To evaluate the applications of AI technologies such as Machine Learning (ML), Natural Language Processing (NLP), and Robotic Process Automation (RPA) in pharmaceutical regulatory submissions.
4. To identify the opportunities and benefits of AI-driven eCTD systems in the Indian pharmaceutical industry.
5. To analyse the challenges and implementation barriers associated with adoption of AI-driven eCTD systems and eCTD 4.0 in India

8. MATERIALS AND METHODS

8.1 Research Design and Study Type

This study employs a systematic review framework to examine the integration of artificial intelligence within the electronic Common Technical Document submission process in the pharmaceutical industry. The research is non-experimental and descriptive, prioritizing the synthesis of secondary data to assess current practices and technological trends. An analytical approach is used to evaluate findings across multiple studies, while a comparative component contrasts traditional manual workflows with automated systems.

8.2 Sources of Data

Data were collected from established academic databases and regulatory repositories, including PubMed, Google Scholar, ScienceDirect, and the official portals of the United States Food and Drug Administration, the European Medicines Agency, and the Central Drugs Standard Control Organization.

8.3 Data Collection and Selection Criteria

The literature search targeted publications released between 2020 and 2025. Identification of relevant material was conducted using specific keywords such as artificial intelligence in regulatory affairs, eCTD automation, and pharmaceutical submissions. Articles were selected based on their technical relevance, source credibility, and the availability of comprehensive data. Selection was limited to expert-reviewed, English-written publications and sector reports centered on regulation processes. Conversely, the study excluded materials published prior to 2020, non-peer-reviewed sources, and research unrelated to pharmaceutical regulatory processes.

8.4 Data Analysis Method

The collected information was analyzed through qualitative and comparative methods. Findings were categorized into thematic areas, including specific AI technologies, implementation tools, operational benefits, and existing challenges. This categorization allowed for the identification of broader industry trends and the assessment of automation efficiency.

8.5 Comparative Regulatory Analysis

A focused comparison of regulatory frameworks from international agencies and the Indian regulatory authority was performed. This analysis evaluated regional differences in submission requirements, the maturity of digital adoption, and the formal acceptance of AI-driven methodologies.

8.6 Ethical Considerations and Limitations

As the research is based entirely on publicly available secondary data, it did not involve human or animal subjects. Standard academic practices for citation and attribution were followed to ensure research integrity. Study limitations include a reliance on existing literature and restricted access to proprietary industry data. Additionally, the rapid evolution of AI technologies and varying levels of regulatory acceptance across different jurisdictions may affect the long-term applicability of the findings.

8.7 Expected Outcomes and Case Study Analysis

The study intends to identify the primary AI technologies currently utilized in regulatory submissions and to evaluate their specific impact on the Indian pharmaceutical sector. To contextualize these findings, the research incorporates an analysis of selected case studies from published literature. These cases serve to illustrate practical implementation, performance improvements, and the technical hurdles encountered during the adoption of automated systems.

CONCLUSION

The transition from conventional Common Technical Document (CTD) systems to electronic Common Technical Document (eCTD) platforms has significantly improved the efficiency and standardization of pharmaceutical regulatory submissions. The emergence of eCTD 4.0 has further strengthened digital regulatory operations through structured content management, advanced metadata handling, interoperability, and improved lifecycle management. These advancements have created a strong foundation for the integration of Artificial Intelligence (AI) and automation technologies in regulatory affairs.

This review highlights the growing role of AI technologies such as Machine Learning (ML), Natural Language Processing (NLP), and Robotic Process Automation (RPA) in transforming eCTD submission processes. AI-driven systems support automated document classification, metadata generation, validation, compliance monitoring, regulatory intelligence, and workflow management, thereby reducing manual effort, minimizing errors, and improving submission quality and review efficiency. In addition, digital tools including Electronic Document Management Systems (EDMS), Regulatory Information Management (RIM) systems, cloud-based platforms, and blockchain technologies further enhance data management, traceability, and operational efficiency.

Despite these advantages, several challenges continue to limit the widespread implementation of AI-driven regulatory automation, particularly in the Indian pharmaceutical industry. Major barriers include inadequate digital infrastructure, high implementation costs, limited regulatory harmonization, data privacy concerns, lack of skilled professionals, and the need for transparent and explainable AI systems. Regulatory acceptance, ethical governance, and robust validation frameworks remain essential for sustainable adoption.

Overall, AI-driven automation has the potential to reshape pharmaceutical regulatory submissions into more efficient, accurate, and data-driven processes. Continued advancements in digital technologies, stronger regulatory frameworks, global harmonization initiatives, and increased industry preparedness are expected to accelerate the adoption of AI-enabled eCTD systems in the future. India, through initiatives such as the CDSCO SUGAM platform and ongoing digital transformation efforts, has significant opportunities to strengthen its regulatory ecosystem and align with evolving global regulatory standards.

The gradual adoption of AI-enabled eCTD systems reflects a broader transition from traditional document-centred regulatory practices toward more data-oriented and digitally integrated regulatory management.

CONFLICTS OF INTEREST:

The authors declare no conflict of interest. This review is based on publicly available regulatory and scientific literature, and no financial or personal relationships have influenced its preparation or conclusions

REFERENCES

1. Pawar VT, Jadhav SP, Bhamare MS, Mahajan SK. Regulatory affairs in pharmaceutical industry. Asian J Pharm Res. 2026;16(1):1-5.
2. Khanderao GJ, Kubde JA, Hatwar PR, Bakal RL, Karule VG. A review on role of drug regulatory affairs in pharma industry. Int J Pharm Sci Drug Anal. 2025;5(1):192-200.
3. Wagh S, Waghmare SU, Narode P, Shelke P, Borhade V, Kawar R. Regulatory affairs: global perspectives. Int J Pharm Sci. 2024;2(6):1052-1067.
4. Salunkhe P, Nagrale S. Electronic common technical document (eCTD): structure, submission process and regulatory updates. Int J Drug Regul Aff. 2026;14(1):42-50.
5. Dagade S, Chaudhari B. Global harmonization of CTD and eCTD. Int J Pharm Sci. 2026;4(4):1191-1202.
6. Mahaparale S, Desai B. CTD and eCTD implementation overview. World J Pharm Res. 2018;7(7):201-215.
7. Ahammad N, Reddy N, Nagabhushanam MV, Ramakrishna B. Challenges in CTD/eCTD submissions for USFDA and Canada. J Drug Deliv Ther. 2019;9(4 Suppl):673-679.
8. Chaudhari SP, Telrandhe SG, Adhav V, Taktode A. eCTD submission in Europe: regulatory requirements and best practices. Int J Res Anal Rev. 2023;10(3):29-35.
9. Sudesamithiran N. Next generation eCTD review. Int J Drug Regul Aff. 2023;11(4):67-73.
10. Nagar K, Choudhary M, Yadav B, Rahi S, Upadhayay A. Transition to eCTD 4.0. Int J Drug Regul Aff. 2025;13(3):77-84.
11. Venna SR. Optimising global eCTD submissions: harmonisation challenges. Indo Am J Pharm Biol Sci. 2020;18(1):13-18.
12. Boopathi LK, Raja N. AI and machine learning in regulatory affairs. Int J Drug Regul Aff. 2024;12(4):102-110.
13. Amarlapudi E, Akhil P, Divya D, Gremya B, Devayani T. Artificial intelligence and machine learning in revolutionizing pharmaceutical regulatory affairs. Int J Pharm Sci. 2025;3(4):1986-1993.
14. Ananthan S. AI in pharmaceutical regulatory affairs and MSL activities. Int J Drug Regul Aff. 2025;13(4):52-56.
15. Fu L, Jia G, Liu Z, et al. AI applications in drug regulation: global perspective. Acta Pharm Sin B. 2025;15(1):1-14.
16. Muppalla A, Maddi BD, Maddi NV. AI in regulatory compliance. Int J Drug Regul Aff. 2025;13(2):73-80.
17. Jagtap S, Ali SS. AI for regulatory dossier automation. World J Pharm Res. 2026;15(8):23-35.
18. Shaikh AN, Syed SA. Reinventing drug development and regulatory affairs through artificial intelligence. Int J Drug Regul Aff. 2026;14(1):71-77.
19. Bhatt SS, Parmar R. AI in eCTD submission and review. Int J Creat Res Thoughts. 2026;14(3).
20. Kulkov I. AI in pharmaceutical business transformation. Technol Soc. 2021;66:101629.
21. Pawar HB, Neelanshu, Bhat GM, Srikanth A, Muragundi PM. Challenges of using AI-based NLP tools in regulatory documentation. J Appl Pharm Sci. 2025.
22. Shah MB. AI-driven metadata management. Int J Adv Res Electr Electron Instrum Eng. 2019;8(7):2009.
23. Modalavalasa G. AI-driven data governance. PSPC. 2025;52(1):3.
24. Chandrasekaran K, Pramod Kumar TM, Balamuralidhara V. Regulatory automation tools overview. Int J Drug Regul Aff. 2024;12(1):36-39.
25. Venna SR. Regulatory operations in the digital age: optimizing eCTD workflows with data analytics. Indo Am J Pharm Biol Sci. 2019;17(2):20.
26. Venna SR. Intelligent metadata-driven automation for eCTD 4.0 lifecycle management using explainable artificial intelligence. SSRN. 2025.
27. Mane A, Nagrale S. Global regulatory frameworks (USFDA, EMA, CDSCO). Int J Drug Regul Aff. 2026;14(1):33-41.
28. International Council for Harmonisation. CTD guideline M4. Geneva: ICH; 2004.
29. International Council for Harmonisation. M8 eCTD implementation package. Geneva: ICH; 2022.
30. US Food and Drug Administration. eCTD submission specifications guidance. Silver Spring: FDA; 2022.
31. US Food and Drug Administration. Electronic submission format guidance. Silver Spring: FDA; 2024.
32. European Medicines Agency. Submission roadmap and eCTD requirements. Amsterdam: EMA; 2024.
33. Health Canada. eCTD regulatory guidance. Ottawa: Health Canada; 2023.
34. Central Drugs Standard Control Organization. eCTD and SUGAM portal guidance. New Delhi: CDSCO; 2024.
35. Ahmed S. eCTD 4.0 implementation including understanding of regional differences and benefits. IQVIA; 2023.
36. Kimta A, Dogra R. AI in Indian pharmaceutical sector. Int J Nov Res Dev. 2024;9(4).
37. PharmaRegulatory.in. CDSCO eCTD pilot program India roadmap [Internet]. 2025 [cited 2026 Mar 15]. Available from: https://pharmaregulatory.in
38. PharmaRegulatory.in. AI in eCTD compilation and review [Internet]. 2025 [cited 2026 Mar 15]. Available from: https://pharmaregulatory.in
39. PharmaRegulatory.in. Regulatory case studies and best practices [Internet]. 2025 [cited 2026 Mar 15]. Available from: https://pharmaregulatory.in
40. Kivo. Everything you need to know about eCTD 4.0 [Internet]. 2025 [cited 2026 Mar 15]. Available from: https://kivo.io
41. Nagar K, Rahi S, Isfaq M. A study on identifying gaps in traditional regulatory dossier processes and the role of artificial intelligence in streamlining submission workflows. World J Pharm Sci Res. 2026;5(1):27-39.
42. Bhavsar D. eCTD adoption trends and regulatory impact. Sarcouncil J Med Ser. 2024;9.
43. Bhavsar DJ. Strategic project management in regulatory affairs. Int Res J Adv Sci Hub. 2025;7(7):630-636.
44. Pawar KS. Regulatory submission readiness using eCTD metrics. J Regul Aff Qual Assur. 2025;1(1):27.
45. Raj RK, Pattanaik P, Roy H. The dynamics of global pharma regulatory affairs system. Indo Am J Pharm Biol Sci.